Fisher & Paykel Healthcare to challenge ResMed for market share

This NZ-based medical devices company is up over 50% in the last six months.

a woman

Fisher & Paykel (ASX: FPH), is arguably New Zealand’s answer to ResMed (ASX: RMD). The company has over 2,750 employees in 33 countries and sells its products to over 17,000 customers. It has about 2,800 products and 100 distributors (although it also employ its own direct sales team in certain markets).

Fisher & Paykel specialises in respiratory devices, and earns more than 40% of its revenue from devices that treat obstructive sleep apnea (OSA). These devices compete directly with those offered by ResMed. Treatment of OSA requires a machine that controls the air pressure, a mask to deliver the oxygen to the patient, and, for those that want it, a humidifier.

Fisher & Paykel has recently announced the launch of its new mask, which it hopes will give it an edge over the competition. In the past, mask design has focused on making the masks less uncomfortable for patients. With its latest offering, the Pilairo Q, Fisher & Paykel have taken into consideration the comfort of the partners of those with OSA.

The key selling point of the new mask is that it is “virtually silent”. This addresses one of the major drawbacks of treatment. Breathing out through the older masks is so noisy that some patients resort to listening to music to obscure the sound. The opportunity to reduce the impact on a partner is likely to be a strong selling point for both the Pilairo Q mask and, as a consequence, the company’s SensAwake machine.

Fisher & Paykel generates the majority of its revenue by supplying hospitals with a range of devices that allow patients to breathe more easily. The treatment of OSA is within the company’s field of expertise, but it only entered that market about a decade ago. CEO Michael Daniell estimates that the company supplies about 8% of the market for OSA devices. The clear strategy is to use technical innovation to improve market share.

In the last few years, Fisher & Paykel has been taking on more debt. At the end of FY 2013 it had about $135 million in interest bearing liabilities, up more than 15% on 2012. Interest payments are now 5.6% of operating cash flow. While this does not threaten the viability of the company, it is unnecessary. The company pays a 3% unfranked dividend at current prices. Unfortunately, it also has unlisted options equal to about 3.4% of the current number of shares on issue.

Foolish takeaway

Fisher & Paykel is currently priced for double-digit growth for at least another five years. In my opinion, shares offer no margin of safety at current prices. Nevertheless, the company is worthy of a spot on your watchlist. Shareholders of ResMed should also take note — Fisher & Paykel has the expertise and ability to seriously compete from across the Tasman.

Looking for a dividend paying stock that isn’t too expensive? Discover The Motley Fool’s favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of “The Motley Fool’s Top Dividend Stock for 2013-2014.

More reading

Motley Fool contributor Claude Walker does not own shares in any of the companies mentioned in this article. Find him on Twitter @claudedwalker.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

person reading news on mobile phone
⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »